Investors should monitor the upcoming Phase 3 CHAPTER-3 topline data in Q3 2026 as the next major catalyst; successful results could drive significant upside given the lack of oral options in HAE and strong Phase 2/3 signals to date.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 20 $26.00entry
- T+1 · 8mo ago −1.15%α −2.26% · $25.70
- T+5 · 8mo ago +5.19%α +7.34% · $27.35
- T+20 · 7mo ago +11.42%α +2.10% · $28.97
- T+60 · 5mo ago +21.31%α +6.89% · $31.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris announced the publication of positive Phase 2 data from its CHAPTER-1 and RAPIDe-1 trials in The Lancet Haematology, showing deucrictibant's efficacy and safety as both a prophylactic and on-demand oral treatment for hereditary angioedema (HAE). The results support its potential as a first-in-class oral B2 receptor antagonist for end-to-end HAE management, with Phase 3 topline data expected in Q3 2026.
Key Facts
- Phase 2 CHAPTER-1 trial showed statistically significant reduction in HAE attack frequency with deucrictibant for prophylaxis.
- Phase 2 RAPIDe-1 trial demonstrated statistically significant reduction in attack severity and faster symptom relief for on-demand treatment.
- Deucrictibant is an oral bradykinin B2 receptor antagonist, positioning it as a potential first-in-class oral therapy for both prevention and acute treatment of HAE.
- Topline data from pivotal Phase 3 RAPIDe-3 trial already confirmed faster symptom relief and single-capsule resolution in most attacks.
- Marketing authorization applications for deucrictibant immediate-release capsule are being prepared, with NDA submission expected in first half of 2026.
- Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland.
Financial Impact
Potential blockbuster revenue if approved, given deucrictibant's dual indication and oral convenience in a chronic, high-cost rare disease market.
Risk Factors
- Phase 3 data may not replicate Phase 2 results, particularly in larger, more diverse populations.
- Regulatory delays or rejections despite strong data, especially given the novelty of the oral B2 antagonist mechanism.
- Competition from existing injectable therapies and emerging oral kallikrein inhibitors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259646 |
Track record
51 reports on PHVS
14 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers